Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
New Active Ingredient + Innovative Drug Delivery System = Business Success More
A liquid system which enables rapid transmigration of therapeutic doses of up to large molecules More
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
Aerosolized pharmaceutical composition with low potential toxicity, significantly reducing airway inflammation and remodelling More
1,2,4-benzothiadiazine derivatives useful for the treatment of endocrinological system diseases such as hyperinsulinaemia and diabetes. More
The development of a transdermal therapeutic system offers the advantages of constant plasma levels i.e. avoiding of plasma peaks and providing of therapeutic plasma level during the early morning hours More
A new veterinary medicinal composition designed to maintain the oxygenic consumption, to restore hydric, electrolytic and energetic status, as well as the blood pH in affected mammals. More
1217B is a botanically derived potential drug candidate that inhibits the synthesis of several key pro-inflammatory mediators involved in the pathophysiology of allergic asthma and has been found to improve lung functionality in a mouse model. More
New substituted phenyl compounds useful for the treatment of respiratory disorders e.g. extrinsic or intrinsic or atopic asthma, chronic bronchitis, bronchiectasis and emphysema - multifunctional ?-agonist compounds comprising a reactive oxygen... More
Your selection
Browse By
- Therapeutic target
- Adult respiratory distress syndrome
- Allergy, respiratory
- Asthma
- Asthma, bronchospasm
- Bronchitis
- Chest disorder (other)
- Chlamydia pneumoniae
- Chronic obstructive pulmonary disease
- Cough
- Cystic fibrosis
- Dysplasia, bronchopulmonary
- Emphysema
- Granulomatous lung disease sarcoidosis
- Idiopathic respiratory distress syndrome
- Meconium aspiration syndrome
- Nasal disorder (other)
- Obstructive airway disease
- Pneumonia
- Pneumonocystis carinii lung infection
- Pseudomonas lung infection
- Respiratory disorder (other)
- Respiratory syncytial virus
- Respiratory tract infections
- Rhinitis
- Rhinovirus (common cold)
- Sinusitis
- Sleep apnea
- Throat disorder (other)
- Tuberculosis
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us